Clinical Trial Update: Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant FOLFIRINOX plus pembrolizumab followed by surgery for resectable pancreatic ductal adenocarcinoma; currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• FOLFIRINOX regimen (5-fluorouracil, leucovorin, oxaliplatin, irinotecan)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: RECRUITING